Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) in combined treatment of ovarian cancer patients

Yarema R.R. 1, Fetsych Т.G.1, Volodko N.A. 1, Ohorchak М.А.2, Mylyan Y.P. 2, Fetsych M.T.

Summary. A study of the clinical efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the combined treatment of ovarian cancer patients with peritoneal metastasis and explore prognostic factors in these patients. The analysis of the effectiveness of cytoreductive surgery, HIPEC and systemic chemotherapy in the combined treatment of 59 patients with ovarian cancer and peritoneal carcinomatosis (49 patients with recurrent ovarian cancer and 10 patients with primary ovarian cancer). HIPEC was conducted in a «closed» procedure using cisplatin or cisplatin in combination with doxorubicin. Postoperative surgical complications developed in 22% of patients, 60-day postoperative mortality was 6.8%. The disease-free and overall median survival of patients was 13.9 and 30.2 months, respectively. Within univariate analysis of the likely impact on survival characterized by the following factors: presence of ascites, chemosensitivity and duration of disease-free period in patients with recurrent ovarian cancer, peritoneal cancer index, completeness of cytoreduction and presence of extraperitoneal metastases. The use of aggressive combined treatment of ovarian cancer with peritoneal carcinomatosis using cytoreductive surgery and HIPEC demonstrates acceptable immediate results and promising survival rates of patients.
Follow us on social media:
No Comments » Add your
Leave a comment